Tampa General Hospital (TGH) and the collaborative pulmonology program of USF Health have joined the Foundation for Sarcoidosis Research (FSR) Global Sarcoidosis Clinic Alliance to advance care and research in sarcoidosis. The Alliance is a hub of clinics and hospitals around the world, that through education,…
The first participant has been dosed in a Phase 2 clinical trial testing the experimental therapy namilumab in people with pulmonary sarcoidosis, the therapy’s developer Kinevant Sciences announced. “We are excited to advance namilumab as a promising new treatment for pulmonary sarcoidosis since it has a mechanism of…
The Foundation for Sarcoidosis Research (FSR) has awarded pulmonologist Nabeel Hamzeh, MD, at the University of Iowa, a $50,000 grant to develop blood biomarkers of cardiac sarcoidosis. His project, titled “Cardiac-Specific Cell Free DNA Biomarkers for Cardiac Sarcoidosis,” will focus on the biomarker potential of heart cell-specific circulating cell-free…
Among sarcoidosis patients referred for lung transplant, the risk of death while on the waitlist is higher for women and those who have severe pulmonary hypertension (PH), or high blood pressure in the lungs, a new study reports. “Clinicians should be mindful of the increased mortality in [advanced…
Infliximab — marketed as Remicade and biosimilars — had steroid-sparing effects superior to methotrexate in the treatment of cardiac sarcoidosis, a small study found. The success rate of a tapering course of corticosteroids was significantly better when infliximab was added to the regimen than when the steroid was used…
Xentria has raised $25 million in funding to further the development of XTMAB-16, its experimental antibody therapy for sarcoidosis. The funding will allow for the launch of a global clinical trial of XTMAB-16 in sarcoidosis patients, planned to start early next year. “I am excited about this…
A new type of biochemical analysis called ACE phenotyping may help diagnose sarcoidosis involvement outside the lungs, a study proposes. “We believe that our method allows for the noninvasive detection of patients with systemic sarcoidosis,” the researchers wrote. The study, “Predictive potential of ACE phenotyping in…
About 35 out of every 100,000 people with private insurance in the U.S. are estimated to have sarcoidosis, and most disease clusters are located near urban areas on the East Coast, a new study shows. However, most of these clusters disappeared when controlling for race, “suggesting that geographical racial…
A Phase 3 clinical trial testing the ability of efzofitimod to safely improve lung function and reduce corticosteroid usage in adults with pulmonary sarcoidosis has dosed its first participant. The aTyr Pharma-sponsored study, dubbed EFZO-FIT, will take place at multiple centers in North America, Europe, and Japan.
The Ann Theodore Foundation and the Milken Institute have awarded more than $3 million to six research teams nationwide to study sarcoidosis topics ranging from risk factors for the poorly understood disease to its underlying mechanisms. The Ann Theodore Foundation Breakthrough Sarcoidosis Initiative grant program seeks to understand…
Get regular updates to your inbox.